CD47 (Japanese Wikipedia)

Analysis of information sources in references of the Wikipedia article "CD47" in Japanese language version.

Last modified: 14:31:55, 21 November 2025 (UTC)

Ref.Un. Ref.Website

Global rank Japanese rank

5^th place

11^th place

2^nd place

3^rd place

4^th place

12^th place

33adsabs.harvard.edu

14^th place

60^th place

11medicalxpress.com

low place

low place

240^th place

749^th place

adsabs.harvard.edu (Global: 14^th place; Japanese: 60^th place)

ui.adsabs.harvard.edu

“Role of CD47 as a marker of self on red blood cells”. Science 288 (5473): 2051–4. (June 2000). Bibcode:2000Sci...288.2051O. doi:10.1126/science.288.5473.2051. PMID 10856220.
“Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response”. Proc. Natl. Acad. Sci. U.S.A. 110 (27): 11103–8. (July 2013). Bibcode:2013PNAS..11011103T. doi:10.1073/pnas.1305569110. PMC 3703977. PMID 23690610.
Unanue ER (July 2013). “Perspectives on anti-CD47 antibody treatment for experimental cancer”. Proc. Natl. Acad. Sci. U.S.A. 110 (27): 10886–7. Bibcode:2013PNAS..11010886U. doi:10.1073/pnas.1308463110. PMC 3704033. PMID 23784781.

caltech.edu (Global: 240^th place; Japanese: 749^th place)

authors.library.caltech.edu

“Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors”. Science Translational Medicine 9 (381): eaaf2968. (March 2017). doi:10.1126/scitranslmed.aaf2968. PMID 282984186

doi.org (Global: 2^nd place; Japanese: 3^rd place)

“CD47 update: a multifaceted actor in the tumour microenvironment of potential therapeutic interest”. Br. J. Pharmacol. 167 (7): 1415–30. (December 2012). doi:10.1111/j.1476-5381.2012.02099.x. PMC 3514757. PMID 22774848.
“CD47 expression in cryopreserved equine cutaneous masses and normal skin”. Journal of Veterinary Diagnostic Investigation 28 (4): 408–13. (July 2016). doi:10.1177/1040638716643352. PMID 27154320.
“In vivo expression of alternatively spliced forms of integrin-associated protein (CD47)”. J. Cell Sci. 108 (Pt 11): 3419–25. (November 1995). doi:10.1242/jcs.108.11.3419. PMID 8586654.
“CD47 is necessary for inhibition of nitric oxide-stimulated vascular cell responses by thrombospondin-1”. J. Biol. Chem. 281 (36): 26069–80. (September 2006). doi:10.1074/jbc.M605040200. PMID 16835222.
“Table 1: The Single Nucleotide Polymorphisms in cathepsin B protein mined from literature (PMID: 16492714).”. dx.doi.org. 2023年5月26日閲覧。
“Integrin-associated protein (CD47) and its ligands”. Trends Cell Biol. 11 (3): 130–5. (March 2001). doi:10.1016/S0962-8924(00)01906-1. PMID 11306274.
Logtenberg, Meike E. W.; Scheeren, Ferenc A.; Schumacher, Ton N. (2020-05-19). “The CD47-SIRPα Immune Checkpoint”. Immunity 52 (5): 742–752. doi:10.1016/j.immuni.2020.04.011. ISSN 1097-4180. PMC 7340539. PMID 32433947.
Smadja, David M.; d'Audigier, Clément; Bièche, Ivan; Evrard, Solène; Mauge, Laetitia; Dias, Juliana-Vieira; Labreuche, Julien; Laurendeau, Ingrid et al. (2011-03). “Thrombospondin-1 is a plasmatic marker of peripheral arterial disease that modulates endothelial progenitor cell angiogenic properties”. Arteriosclerosis, Thrombosis, and Vascular Biology 31 (3): 551–559. doi:10.1161/ATVBAHA.110.220624. ISSN 1524-4636. PMID 21148423.
Ghimire, Kedar; Li, Yao; Chiba, Takuto; Julovi, Sohel M.; Li, Jennifer; Ross, Mark A.; Straub, Adam C.; O'Connell, Philip J. et al. (2020-07-15). “CD47 Promotes Age-Associated Deterioration in Angiogenesis, Blood Flow and Glucose Homeostasis”. Cells 9 (7): 1695. doi:10.3390/cells9071695. ISSN 2073-4409. PMC 7407670. PMID 32679764.
Kojima, Yoko; Volkmer, Jens-Peter; McKenna, Kelly; Civelek, Mete; Lusis, Aldons Jake; Miller, Clint L.; Direnzo, Daniel; Nanda, Vivek et al. (2016-08-04). “CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis”. Nature 536 (7614): 86–90. doi:10.1038/nature18935. ISSN 1476-4687. PMC 4980260. PMID 27437576.
“Endothelial CD47 promotes vascular endothelial-cadherin tyrosine phosphorylation and participates in T cell recruitment at sites of inflammation in vivo”. J. Immunol. 189 (5): 2553–62. (September 2012). doi:10.4049/jimmunol.1103606. PMC 3424398. PMID 22815286.
“Role of CD47 as a marker of self on red blood cells”. Science 288 (5473): 2051–4. (June 2000). Bibcode:2000Sci...288.2051O. doi:10.1126/science.288.5473.2051. PMID 10856220.
“The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications”. Curr. Opin. Immunol. 24 (2): 225–32. (April 2012). doi:10.1016/j.coi.2012.01.010. PMC 3319521. PMID 22310103.
“Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors”. Science Translational Medicine 9 (381): eaaf2968. (March 2017). doi:10.1126/scitranslmed.aaf2968. PMID 282984186
“Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47”. Sci Transl Med 2 (63): 63ra94. (December 2010). doi:10.1126/scitranslmed.3001375. PMC 4126904. PMID 21178137.
“Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response”. Proc. Natl. Acad. Sci. U.S.A. 110 (27): 11103–8. (July 2013). Bibcode:2013PNAS..11011103T. doi:10.1073/pnas.1305569110. PMC 3703977. PMID 23690610.
Unanue ER (July 2013). “Perspectives on anti-CD47 antibody treatment for experimental cancer”. Proc. Natl. Acad. Sci. U.S.A. 110 (27): 10886–7. Bibcode:2013PNAS..11010886U. doi:10.1073/pnas.1308463110. PMC 3704033. PMID 23784781.
Chao, Mark P.; Alizadeh, Ash A.; Tang, Chad; Myklebust, June H.; Varghese, Bindu; Gill, Saar; Jan, Max; Cha, Adriel C. et al. (2010-09-03). “Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma”. Cell 142 (5): 699–713. doi:10.1016/j.cell.2010.07.044. ISSN 1097-4172. PMC 2943345. PMID 20813259.
Gholamin, Sharareh; Mitra, Siddhartha S.; Feroze, Abdullah H.; Liu, Jie; Kahn, Suzana A.; Zhang, Michael; Esparza, Rogelio; Richard, Chase et al. (2017-03-15). “Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors”. Science Translational Medicine 9 (381): eaaf2968. doi:10.1126/scitranslmed.aaf2968. ISSN 1946-6242. PMID 28298418.

medicalxpress.com (Global: low place; Japanese: low place)

“Fibrosis reversed when 'don't eat me' signal blocked, study finds”. medicalxpress.com. 2023年6月3日閲覧。

nih.gov (Global: 5^th place; Japanese: 11^th place)

pubmed.ncbi.nlm.nih.gov

“CD47 update: a multifaceted actor in the tumour microenvironment of potential therapeutic interest”. Br. J. Pharmacol. 167 (7): 1415–30. (December 2012). doi:10.1111/j.1476-5381.2012.02099.x. PMC 3514757. PMID 22774848.
“CD47 expression in cryopreserved equine cutaneous masses and normal skin”. Journal of Veterinary Diagnostic Investigation 28 (4): 408–13. (July 2016). doi:10.1177/1040638716643352. PMID 27154320.
“In vivo expression of alternatively spliced forms of integrin-associated protein (CD47)”. J. Cell Sci. 108 (Pt 11): 3419–25. (November 1995). doi:10.1242/jcs.108.11.3419. PMID 8586654.
“CD47 is necessary for inhibition of nitric oxide-stimulated vascular cell responses by thrombospondin-1”. J. Biol. Chem. 281 (36): 26069–80. (September 2006). doi:10.1074/jbc.M605040200. PMID 16835222.
“Integrin-associated protein (CD47) and its ligands”. Trends Cell Biol. 11 (3): 130–5. (March 2001). doi:10.1016/S0962-8924(00)01906-1. PMID 11306274.
Logtenberg, Meike E. W.; Scheeren, Ferenc A.; Schumacher, Ton N. (2020-05-19). “The CD47-SIRPα Immune Checkpoint”. Immunity 52 (5): 742–752. doi:10.1016/j.immuni.2020.04.011. ISSN 1097-4180. PMC 7340539. PMID 32433947.
Smadja, David M.; d'Audigier, Clément; Bièche, Ivan; Evrard, Solène; Mauge, Laetitia; Dias, Juliana-Vieira; Labreuche, Julien; Laurendeau, Ingrid et al. (2011-03). “Thrombospondin-1 is a plasmatic marker of peripheral arterial disease that modulates endothelial progenitor cell angiogenic properties”. Arteriosclerosis, Thrombosis, and Vascular Biology 31 (3): 551–559. doi:10.1161/ATVBAHA.110.220624. ISSN 1524-4636. PMID 21148423.
Ghimire, Kedar; Li, Yao; Chiba, Takuto; Julovi, Sohel M.; Li, Jennifer; Ross, Mark A.; Straub, Adam C.; O'Connell, Philip J. et al. (2020-07-15). “CD47 Promotes Age-Associated Deterioration in Angiogenesis, Blood Flow and Glucose Homeostasis”. Cells 9 (7): 1695. doi:10.3390/cells9071695. ISSN 2073-4409. PMC 7407670. PMID 32679764.
Kojima, Yoko; Volkmer, Jens-Peter; McKenna, Kelly; Civelek, Mete; Lusis, Aldons Jake; Miller, Clint L.; Direnzo, Daniel; Nanda, Vivek et al. (2016-08-04). “CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis”. Nature 536 (7614): 86–90. doi:10.1038/nature18935. ISSN 1476-4687. PMC 4980260. PMID 27437576.
“Endothelial CD47 promotes vascular endothelial-cadherin tyrosine phosphorylation and participates in T cell recruitment at sites of inflammation in vivo”. J. Immunol. 189 (5): 2553–62. (September 2012). doi:10.4049/jimmunol.1103606. PMC 3424398. PMID 22815286.
“Role of CD47 as a marker of self on red blood cells”. Science 288 (5473): 2051–4. (June 2000). Bibcode:2000Sci...288.2051O. doi:10.1126/science.288.5473.2051. PMID 10856220.
“The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications”. Curr. Opin. Immunol. 24 (2): 225–32. (April 2012). doi:10.1016/j.coi.2012.01.010. PMC 3319521. PMID 22310103.
“Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors”. Science Translational Medicine 9 (381): eaaf2968. (March 2017). doi:10.1126/scitranslmed.aaf2968. PMID 282984186
“Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47”. Sci Transl Med 2 (63): 63ra94. (December 2010). doi:10.1126/scitranslmed.3001375. PMC 4126904. PMID 21178137.
“Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response”. Proc. Natl. Acad. Sci. U.S.A. 110 (27): 11103–8. (July 2013). Bibcode:2013PNAS..11011103T. doi:10.1073/pnas.1305569110. PMC 3703977. PMID 23690610.
Unanue ER (July 2013). “Perspectives on anti-CD47 antibody treatment for experimental cancer”. Proc. Natl. Acad. Sci. U.S.A. 110 (27): 10886–7. Bibcode:2013PNAS..11010886U. doi:10.1073/pnas.1308463110. PMC 3704033. PMID 23784781.
Chao, Mark P.; Alizadeh, Ash A.; Tang, Chad; Myklebust, June H.; Varghese, Bindu; Gill, Saar; Jan, Max; Cha, Adriel C. et al. (2010-09-03). “Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma”. Cell 142 (5): 699–713. doi:10.1016/j.cell.2010.07.044. ISSN 1097-4172. PMC 2943345. PMID 20813259.
Gholamin, Sharareh; Mitra, Siddhartha S.; Feroze, Abdullah H.; Liu, Jie; Kahn, Suzana A.; Zhang, Michael; Esparza, Rogelio; Richard, Chase et al. (2017-03-15). “Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors”. Science Translational Medicine 9 (381): eaaf2968. doi:10.1126/scitranslmed.aaf2968. ISSN 1946-6242. PMID 28298418.

ncbi.nlm.nih.gov

“CD47 update: a multifaceted actor in the tumour microenvironment of potential therapeutic interest”. Br. J. Pharmacol. 167 (7): 1415–30. (December 2012). doi:10.1111/j.1476-5381.2012.02099.x. PMC 3514757. PMID 22774848.
“"Entrez Gene: CD47 CD47 molecule".”. 2023年6月3日閲覧。
“Entrez Gene: CD47 CD47 molecule”. 2023年6月3日閲覧。
Logtenberg, Meike E. W.; Scheeren, Ferenc A.; Schumacher, Ton N. (2020-05-19). “The CD47-SIRPα Immune Checkpoint”. Immunity 52 (5): 742–752. doi:10.1016/j.immuni.2020.04.011. ISSN 1097-4180. PMC 7340539. PMID 32433947.
Ghimire, Kedar; Li, Yao; Chiba, Takuto; Julovi, Sohel M.; Li, Jennifer; Ross, Mark A.; Straub, Adam C.; O'Connell, Philip J. et al. (2020-07-15). “CD47 Promotes Age-Associated Deterioration in Angiogenesis, Blood Flow and Glucose Homeostasis”. Cells 9 (7): 1695. doi:10.3390/cells9071695. ISSN 2073-4409. PMC 7407670. PMID 32679764.
Kojima, Yoko; Volkmer, Jens-Peter; McKenna, Kelly; Civelek, Mete; Lusis, Aldons Jake; Miller, Clint L.; Direnzo, Daniel; Nanda, Vivek et al. (2016-08-04). “CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis”. Nature 536 (7614): 86–90. doi:10.1038/nature18935. ISSN 1476-4687. PMC 4980260. PMID 27437576.
“Endothelial CD47 promotes vascular endothelial-cadherin tyrosine phosphorylation and participates in T cell recruitment at sites of inflammation in vivo”. J. Immunol. 189 (5): 2553–62. (September 2012). doi:10.4049/jimmunol.1103606. PMC 3424398. PMID 22815286.
“The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications”. Curr. Opin. Immunol. 24 (2): 225–32. (April 2012). doi:10.1016/j.coi.2012.01.010. PMC 3319521. PMID 22310103.
“Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47”. Sci Transl Med 2 (63): 63ra94. (December 2010). doi:10.1126/scitranslmed.3001375. PMC 4126904. PMID 21178137.
“Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response”. Proc. Natl. Acad. Sci. U.S.A. 110 (27): 11103–8. (July 2013). Bibcode:2013PNAS..11011103T. doi:10.1073/pnas.1305569110. PMC 3703977. PMID 23690610.
Unanue ER (July 2013). “Perspectives on anti-CD47 antibody treatment for experimental cancer”. Proc. Natl. Acad. Sci. U.S.A. 110 (27): 10886–7. Bibcode:2013PNAS..11010886U. doi:10.1073/pnas.1308463110. PMC 3704033. PMID 23784781.
Chao, Mark P.; Alizadeh, Ash A.; Tang, Chad; Myklebust, June H.; Varghese, Bindu; Gill, Saar; Jan, Max; Cha, Adriel C. et al. (2010-09-03). “Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma”. Cell 142 (5): 699–713. doi:10.1016/j.cell.2010.07.044. ISSN 1097-4172. PMC 2943345. PMID 20813259.

pmc.ncbi.nlm.nih.gov

“CD47 update: a multifaceted actor in the tumour microenvironment of potential therapeutic interest”. Br. J. Pharmacol. 167 (7): 1415–30. (December 2012). doi:10.1111/j.1476-5381.2012.02099.x. PMC 3514757. PMID 22774848.
“Endothelial CD47 promotes vascular endothelial-cadherin tyrosine phosphorylation and participates in T cell recruitment at sites of inflammation in vivo”. J. Immunol. 189 (5): 2553–62. (September 2012). doi:10.4049/jimmunol.1103606. PMC 3424398. PMID 22815286.
“The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications”. Curr. Opin. Immunol. 24 (2): 225–32. (April 2012). doi:10.1016/j.coi.2012.01.010. PMC 3319521. PMID 22310103.
“Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47”. Sci Transl Med 2 (63): 63ra94. (December 2010). doi:10.1126/scitranslmed.3001375. PMC 4126904. PMID 21178137.
“Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response”. Proc. Natl. Acad. Sci. U.S.A. 110 (27): 11103–8. (July 2013). Bibcode:2013PNAS..11011103T. doi:10.1073/pnas.1305569110. PMC 3703977. PMID 23690610.
Unanue ER (July 2013). “Perspectives on anti-CD47 antibody treatment for experimental cancer”. Proc. Natl. Acad. Sci. U.S.A. 110 (27): 10886–7. Bibcode:2013PNAS..11010886U. doi:10.1073/pnas.1308463110. PMC 3704033. PMID 23784781.
Chao, Mark P.; Alizadeh, Ash A.; Tang, Chad; Myklebust, June H.; Varghese, Bindu; Gill, Saar; Jan, Max; Cha, Adriel C. et al. (2010-09-03). “Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma”. Cell 142 (5): 699–713. doi:10.1016/j.cell.2010.07.044. ISSN 1097-4172. PMC 2943345. PMID 20813259.

worldcat.org (Global: 4^th place; Japanese: 12^th place)

search.worldcat.org

Logtenberg, Meike E. W.; Scheeren, Ferenc A.; Schumacher, Ton N. (2020-05-19). “The CD47-SIRPα Immune Checkpoint”. Immunity 52 (5): 742–752. doi:10.1016/j.immuni.2020.04.011. ISSN 1097-4180. PMC 7340539. PMID 32433947.
Smadja, David M.; d'Audigier, Clément; Bièche, Ivan; Evrard, Solène; Mauge, Laetitia; Dias, Juliana-Vieira; Labreuche, Julien; Laurendeau, Ingrid et al. (2011-03). “Thrombospondin-1 is a plasmatic marker of peripheral arterial disease that modulates endothelial progenitor cell angiogenic properties”. Arteriosclerosis, Thrombosis, and Vascular Biology 31 (3): 551–559. doi:10.1161/ATVBAHA.110.220624. ISSN 1524-4636. PMID 21148423.
Ghimire, Kedar; Li, Yao; Chiba, Takuto; Julovi, Sohel M.; Li, Jennifer; Ross, Mark A.; Straub, Adam C.; O'Connell, Philip J. et al. (2020-07-15). “CD47 Promotes Age-Associated Deterioration in Angiogenesis, Blood Flow and Glucose Homeostasis”. Cells 9 (7): 1695. doi:10.3390/cells9071695. ISSN 2073-4409. PMC 7407670. PMID 32679764.
Kojima, Yoko; Volkmer, Jens-Peter; McKenna, Kelly; Civelek, Mete; Lusis, Aldons Jake; Miller, Clint L.; Direnzo, Daniel; Nanda, Vivek et al. (2016-08-04). “CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis”. Nature 536 (7614): 86–90. doi:10.1038/nature18935. ISSN 1476-4687. PMC 4980260. PMID 27437576.
Chao, Mark P.; Alizadeh, Ash A.; Tang, Chad; Myklebust, June H.; Varghese, Bindu; Gill, Saar; Jan, Max; Cha, Adriel C. et al. (2010-09-03). “Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma”. Cell 142 (5): 699–713. doi:10.1016/j.cell.2010.07.044. ISSN 1097-4172. PMC 2943345. PMID 20813259.
Gholamin, Sharareh; Mitra, Siddhartha S.; Feroze, Abdullah H.; Liu, Jie; Kahn, Suzana A.; Zhang, Michael; Esparza, Rogelio; Richard, Chase et al. (2017-03-15). “Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors”. Science Translational Medicine 9 (381): eaaf2968. doi:10.1126/scitranslmed.aaf2968. ISSN 1946-6242. PMID 28298418.